Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (Nasdaq: TWST) has partnered with the CDC to provide customized SARS-CoV-2 Synthetic RNA Controls for the Flu SC2 Multiplex Assay, which tests for influenza and COVID-19. These positive controls enhance quality assurance for next-generation sequencing and RT-PCR assays. The CDC plans to utilize this assay across U.S. public health laboratories. Twist's CEO emphasized the optimization of these controls for stability at room temperature. This initiative reflects Twist's commitment to advancing public health through innovative solutions in bioscience.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily Leproust, Ph.D., will present at the 39th Annual J.P. Morgan Healthcare Conference on January 11th at 5:20 p.m. ET. The presentation will be available via live webcast on the company's investor relations page. A replay will be archived for 30 days post-event. Twist Bioscience specializes in high-quality synthetic DNA production through a proprietary silicon platform. The company focuses on various applications including synthetic genes, next-generation sequencing tools, and biologics drug discovery.
Twist Bioscience Corporation (Nasdaq: TWST) announced plans to offer a new synthetic RNA control including the SARS-CoV-2 variant B1.1.7, which is 70% more transmissible according to preliminary UK data. This new synthetic control will support testing protocols affected by the variant's spike protein mutations. The controls are expected to be available by January 15, 2021, enhancing Twist's ongoing efforts in COVID-19 response. This follows the prior release of SARS-CoV-2 RNA controls for testing and development, establishing Twist as a key player in pandemic management.
Twist Bioscience (NASDAQ: TWST) announced plans to expand its manufacturing capabilities with a new "Factory of the Future" near Portland, Oregon. The 110,000-square-foot facility, expected to be operational in 2022, aims to create up to 400 jobs. CEO Emily M. Leproust emphasized that this facility will enhance production speed and support the growing synthetic biology and biopharma markets, facilitating aggressive growth. This strategic move aligns with Twist's mission to provide high-quality synthetic DNA through its innovative silicon platform.
Twist Bioscience Corporation (NASDAQ: TWST) has launched its Clonal-Ready Gene Fragments, enhancing its synthetic DNA offerings. This product aims to minimize the time and cost associated with screening for perfect clones, addressing a significant segment of the synthetic biology market. The Gene Fragments, produced via Twist's semiconductor-based platform, boast low error rates, which enhance efficiency for researchers needing smaller DNA amounts. This innovation positions Twist to better serve its customers and expand its market reach.
Twist Bioscience Corporation (NASDAQ: TWST) has successfully closed its public offering of 3,211,362 shares at $110.00 each, generating approximately $323.7 million in net proceeds. The offering included shares sold by both the company and certain selling stockholders. Twist plans to utilize these funds to enhance operational capacity, increase R&D investments, and expand its manufacturing capabilities for its synthetic DNA offerings. Additionally, a portion of the proceeds may be allocated towards acquiring complementary businesses.
Twist Bioscience Corporation (NASDAQ: TWST) has priced a public offering of 2,802,272 shares of common stock at $110.00 per share, aiming for approximately $300 million in gross proceeds. The offering includes 2,727,272 shares sold by Twist and 75,000 shares from selling stockholders. Expected to close on December 7, 2020, funds will enhance operational capacity, R&D, and IT infrastructure, with potential investments in complementary businesses. The offering is underwritten by J.P. Morgan, Goldman Sachs, Cowen, and Evercore.
Twist Bioscience Corporation (NASDAQ: TWST) announced its intention to conduct an underwritten public offering of up to $250 million in common stock. Additionally, certain selling stockholders plan to offer 75,000 shares. The offering includes a 30-day option for underwriters to purchase up to $37.5 million more. Twist aims to utilize net proceeds to enhance operational capacity, invest in automation and R&D, and support growth in various sectors, including NGS and DNA data storage.
Twist Bioscience Corporation (NASDAQ: TWST) announced its participation in two upcoming virtual investor conferences. Emily Leproust, CEO, and Jim Thorburn, CFO, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 30 at 8:00 a.m. ET, and the Evercore ISI HealthCONx Conference on December 1 at 1:50 p.m. ET. Both presentations can be accessed on the company’s investor relations website, with replays available for 90 days post-event. Twist Bioscience specializes in synthetic DNA products and applications across multiple industries, including healthcare and agriculture.
Twist Bioscience reported strong financial results for fiscal year 2020 with total revenues increasing to $90.1 million from $54.4 million in fiscal 2019. Total orders rose to $116.7 million. Despite the growth, the company experienced a net loss of $139.9 million, or $3.57 per share. The fourth quarter also saw revenue growth to $32.4 million from $15.7 million year-over-year. With a strong cash position of $290 million, Twist plans aggressive growth in fiscal 2021, focusing on synthetic biology, NGS, and biopharma technologies.